Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 May 30;11(6):1040.
doi: 10.3390/vaccines11061040.

Safety, Tolerability, and Immunogenicity of COVID-19 Bivalent Vaccination

Divyasha Saxena  1 , Lalit Batra  1 , Shailendra Kumar Verma  2
Affiliations
Editorial

Safety, Tolerability, and Immunogenicity of COVID-19 Bivalent Vaccination

Divyasha Saxena et al. Vaccines (Basel). .

Abstract

The COVID-19 pandemic has triggered unparalleled global disruption [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Excler J.-L., Saville M., Berkley S., Kim J.H. Vaccine development for emerging infectious diseases. Nat. Med. 2021;27:591–600. doi: 10.1038/s41591-021-01301-0. - DOI - PubMed
    1. Matkowska-Kocjan A., Owoc-Lempach J., Ludwikowska K., Szenborn F., Moskwa N., Kurek K., Kałwak K., Szenborn L., Ussowicz M. COVID-19 mRNA Vaccine Tolerance and Immunogenicity in Hematopoietic Stem Cell Transplantation Recipients Aged 5–11 Years Old–Non-Randomized Clinical Trial. Vaccines. 2023;11:195. doi: 10.3390/vaccines11010195. - DOI - PMC - PubMed
    1. Moghadas S.M., Vilches T.N., Zhang K., Wells C.R., Shoukat A., Singer B.H., Meyers L.A., Neuzil K.M., Langley J.M., Fitzpatrick M.C., et al. The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. Clin. Infect. Dis. 2021;73:2257–2264. doi: 10.1093/cid/ciab079. - DOI - PMC - PubMed
    1. Shrestha L.B., Foster C., Rawlinson W., Tedla N., Bull R.A. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Rev. Med. Virol. 2022;32:e2381. doi: 10.1002/rmv.2381. - DOI - PMC - PubMed
    1. Chavda V.P., Balar P., Vaghela D., Solanki H.K., Vaishnav A., Hala V., Vora L. Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management. Vaccines. 2023;11:160. doi: 10.3390/vaccines11010160. - DOI - PMC - PubMed

Publication types

LinkOut - more resources